BS_RXN5T5YT
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 1.281208935611038
- age_years
- 10.244
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.525
- HYPOXIA+0.507
- ANGIOGENESIS+0.491
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.476
- COAGULATION+0.472
- INFLAMMATORY_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.431
- IL2_STAT5_SIGNALING+0.371
- MYC_TARGETS_V2+0.353
- MYOGENESIS+0.344
Top 10 suppressed
- PROTEIN_SECRETION-0.425
- OXIDATIVE_PHOSPHORYLATION-0.202
- MYC_TARGETS_V1-0.174
- FATTY_ACID_METABOLISM-0.158
- MITOTIC_SPINDLE-0.153
- ANDROGEN_RESPONSE-0.142
- SPERMATOGENESIS-0.096
- HEME_METABOLISM-0.089
- BILE_ACID_METABOLISM-0.077
- UV_RESPONSE_DN-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.915 |
| 2 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.904 |
| 3 | 82992 | EPN | Supratentorial EPN | 0.904 |
| 4 | BS_0QYS36NR | Ependymoma NOS | — | 0.900 |
| 5 | SRR5088899 | — | — | 0.899 |
| 6 | SJEPD001508_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.882 |
| 7 | b556b718-38cf-498d-94c7-4e240fe57d48 | — | — | 0.880 |
| 8 | BS_QWTE1CWR | high-grade glioma | — | 0.879 |
| 9 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.874 |
| 10 | MNG721 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.525 | Inavolisib | — uncovered |
| HYPOXIA | 0.507 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.491 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.476 | Inavolisib | — uncovered |
| COAGULATION | 0.472 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.431 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.371 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.353 | Idelalisib | — uncovered |
| MYOGENESIS | 0.344 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.342 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.331 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.323 | Idelalisib | — uncovered |
| APOPTOSIS | 0.321 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.317 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.306 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.296 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.288 | Inavolisib | — uncovered |